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OBJECTIVES: To comprehensively classify interventions performed by ICU clin-
ical pharmacists and quantify cost avoidance generated through their accepted 
interventions.
DESIGN: A multicenter, prospective, observational study was performed be-
tween August 2018 and January 2019.
SETTING: Community hospitals and academic medical centers in the United States.
PARTICIPANTS: ICU clinical pharmacists.
INTERVENTIONS: Recommendations classified into one of 38 intervention cat-
egories (divided into six unique sections) associated with cost avoidance.
MEASUREMENTS AND MAIN RESULTS: Two-hundred fifteen ICU pharma-
cists at 85 centers performed 55,926 interventions during 3,148 shifts that were 
accepted on 27,681 adult patient days and generated $23,404,089 of cost avoid-
ance. The quantity of accepted interventions and cost avoidance generated in 
six established sections was adverse drug event prevention (5,777 interventions; 
$5,822,539 CA), resource utilization (12,630 interventions; $4,491,318), individ-
ualization of patient care (29,284 interventions; $9,680,036 cost avoidance), pro-
phylaxis (1,639 interventions; $1,414,465 cost avoidance), hands-on care (1,828 
interventions; $1,339,621 cost avoidance), and administrative/supportive tasks 
(4,768 interventions; $656,110 cost avoidance). Mean cost avoidance was $418 
per intervention, $845 per patient day, and $7,435 per ICU pharmacist shift. The an-
nualized cost avoidance from an ICU pharmacist is $1,784,302. The potential mon-
etary cost avoidance to pharmacist salary ratio was between $3.3:1 and $9.6:1.
CONCLUSIONS: Pharmacist involvement in the care of critically ill patients 
results in significant avoidance of healthcare costs, particularly in the areas of in-
dividualization of patient care, adverse drug event prevention, and resource utiliza-
tion. The potential monetary cost avoidance to pharmacist salary ratio employing 
an ICU clinical pharmacist is between $3.3:1 and $9.6:1.
KEY WORDS: cost; medical care; medication; pharmacist; safety; value
Almost 1.5 million patients were admitted to ICUs in the United States in 2015 (1). The costs associated with providing critical care services in ICUs represented approximately 1% of the U.S. gross domestic product 
(2). Healthcare teams in ICUs have evolved to incorporate practitioners in other 
professions, including pharmacists (3). Many ICU pharmacists complete spe-
cialty residency or fellowship training and are board certified in critical care. The 
role of pharmacists has shifted from preparing and dispensing medications to 
performing direct patient care as a member of multidisciplinary teams. These ac-
tivities have demonstrated improved clinical and financial outcomes across var-
ious patient subpopulations and hospital structures (4–9). Consequently, many 
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professional healthcare organizations consider phar-
macists practicing in the ICU to be essential healthcare 
providers, yet the participation of pharmacists in crit-
ical care units is not universal (10–13).
Previous studies of interventions performed by ICU 
pharmacists have more commonly focused on adverse 
drug event (ADE) prevention and reductions in med-
ication use and costs (4–6). Although two multicenter 
studies performed at the institution level and using in-
surance claims data evaluated a broader scope of clinical 
and economic outcomes, the pharmacists’ specific inter-
ventions and roles in patient care were unknown (7, 8). 
A single contemporary study at an academic medical 
center evaluated a medical ICU pharmacist’s clinical 
activities over a 12-month period and determined the 
cost avoidance (CA) of those activities exceeded $3 mil-
lion with a monetary benefit-to-cost ratio of 24.5:1 (9). 
However, these findings may not be generalizable to 
other ICUs and hospital settings because of the patient 
population, pharmacist’s training and relationships with 
providers, and rounding structure. The purposes of this 
study were to comprehensively classify interventions 
performed by pharmacists in the ICU and quantify CA 
generated through accepted interventions.
METHODS
Study Design
The PHarmacist Avoidance or Reductions in Medical 
costs in CRITically ill adults (PHARM-CRIT) study was 
a multicenter, prospective, observational study that was 
performed in community hospitals and academic med-
ical centers in the United States between August 2018 
and January 2019. Recruitment was performed using 
electronic mail. Invitations were sent to the Society of 
Critical Care Medicine’s (SCCM’s) Clinical Pharmacy 
and Pharmacology section listserv. From this listserv, 
which includes multiple healthcare professionals, in 
addition to pharmacists, clinical pharmacists who pro-
vided direct (rounding with the ICU team) or decentral-
ized (not directly rounding with the ICU team) patient 
care for critically ill adults were eligible for study partici-
pation. Pharmacists completing residency or fellowship 
were ineligible. Only interventions made by a pharma-
cist for patients residing in an ICU were eligible for study 
inclusion. Multiple pharmacists from the same institu-
tion were eligible to participate. In order to maximize 
data capture for pharmacist interventions, no minimum 
or maximum duration of study participation by each 
pharmacist was required; however, participants were 
encouraged to document interventions for 20 shifts. All 
clinical interventions made by participating pharmacists 
during study participation were recorded in REDCap© 
(Version 6.18.1, 2019; Vanderbilt University, Nashville, 
TN) in accordance with best practices (14–16). Only 
interventions for adults 18 years old or older that were 
accepted were included in the analyses.
Data Collection
A comprehensive, evidence-based framework for cat-
egorizing and monetizing CA interventions by critical 
care and emergency medicine pharmacists including 38 
unique interventions within six intervention sections 
was developed by our group a priori and previously 
published (17).These interventions included direct 
cost of medications (e.g., IV to oral conversions) as 
well as potential CA associated with initiating drug 
therapy (e.g., initiating venous thromboembolism 
prophylaxis [Supplemental Table 1, http://links.
lww.com/CCX/A870]). Interventions were classified 
according to 38 different intervention categorizations 
organized into six different sections: ADE prevention, 
resource utilization, individualization of patient care, 
prophylaxis, hands-on care, and administrative and 
supportive tasks. Any intervention that could not be 
classified into one of the 38 intervention categories 
was not recorded or available for study inclusion. All 
participants received training on appropriate docu-
mentation of interventions using the CA framework. 
Interventions were entered at the patient level by each 
individual pharmacist. Pharmacists were encouraged 
to enter these data in real time. Although all interven-
tions (accepted and not accepted) were captured, only 
interventions accepted and implemented by the med-
ical team were included in the CA analysis. The Rush 
University Medical Center Institutional Review Board 
(IRB) served as the central and coordinating IRB (IRB 
number 18021508-IRB01). This study was endorsed 
by the SCCM’s Discovery Research Network and was 
a work product of SCCM’s Clinical Pharmacy and 
Pharmacology Section.
Study Outcomes and Statistical Analysis
The primary outcomes were the quantity and type of 
interventions provided and the potential CA generated 
Observational Study
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from clinical pharmacists practicing in ICU settings. 
The values for CA overall and per patient day were 
calculated by summing the CA for each intervention 
based on values from our previously published sys-
tematic framework and expressed in 2019 U.S. dol-
lars. (17, 18) A sensitivity analysis was conducted 
to evaluate CA from just those interventions with 
the highest quality of evidence (evidence from well-
designed controlled trials with or without randomiza-
tion) according to the Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) 
evidence-to-decision framework (GRADE Ia-IIb 
interventions) (17). These interventions included the 
following: 1) medication route: IV-to-oral conversion 
(resource utilization section), 2) medication route: hy-
pertensive crisis management (resource utilization), 
3) antimicrobial therapy initiation and streamlining 
(individualization of patient care), 4) change venous 
thromboembolism prophylaxis to most appropriate 
agent (prophylaxis), and 5) initiation of venous throm-
boembolism prophylaxis (prophylaxis) (17).
Descriptive statistics were used to characterize the 
data. The Shapiro-Wilks test was used to determine 
normality of continuous data. Normally distributed 
data were expressed as mean (sd); nonnormally distrib-
uted data were expressed as median (interquartile range 
[IQR])The CA per pharmacist shift value was annual-
ized using 240 shifts, which corresponds to five shifts 
per week for 48 weeks to allow for not providing care on 
personal time off and holidays. This annualized CA for 
a pharmacist was compared with the average pharma-
cist’s salary and benefits ($185,470) to calculate a mon-
etary CA to pharmacist salary ratio (18, 19). Analyses 
were performed in Stata (Version 16; StataCorp LLC, 
College Station, TX).
RESULTS
Overall, 302 pharmacists responded to our invitation to 
participate, of whom 215 participated in the study. These 
215 pharmacists at 85 centers completed 3,148 shifts. 
Slightly greater than half of the participating pharma-
cists provided care in a medical ICU (58.6%) or surgical 
ICU (53.0%). More than one third of ICUs had an open 
practice model, and 87.4% of the ICUs had interdis-
ciplinary patient care rounds at least 5 days per week. 
ICU pharmacists spent the majority of their shift pro-
viding direct patient care (median, 5.5 hr [IQR, 4–8 hr]). 
Approximately half of each pharmacist’s shift included 
prospective order verification (median, 4 hr [IQR, 0–6 
hr]). ICU pharmacists most frequently rounded with a 
single service (62.8%) although almost one third of par-
ticipants rounded with two or more services each shift. 
The median number of shifts for participating pharma-
cists was 17 (IQR, 6–20). ICU pharmacists cared for a 
median of 15 patients each day (IQR, 12–22). Most ICU 
pharmacists had been in practice for at least 1 year but 
less than 12 years and were board certified (Table 1).
Of the 56,866 interventions performed by ICU 
pharmacists, 55,926 (99.4%) were accepted. These 
interventions were performed on 27,681 patients in six 
categories: ADE prevention (accepted interventions: 
5,777; percentage of total accepted interventions: 
10.3%), resource utilization (12,630; 22.5%), individ-




ICU Pharmacist  
(N = 215)
Practice areaa  
 Decentralized 42 (19.5)
 Burn ICU 19 (8.8)
 Cardiac ICU (medical) 79 (36.7)
 Cardiac ICU (surgical) 87 (40.5)
 Immunocompromised ICU 23 (10.7)
 Medical ICU 126 (58.6)
 Mixed ICU (medical/surgical) 60 (27.9)
 Neuro ICU (medical/surgical) 80 (37.2)
 Surgical ICU 114 (53.0)
 Trauma ICU 75 (34.9)
Open ICU practice model, n (%) 82 (38.1)
ICU rounding 5–7 d per week, n (%) 188 (87.4)
Beds in ICU practice area,  
 median (IQR)
22 (16–27)
Nonpharmacist providers in practice  
 areab
 
 Advanced practice provider 162 (75.3)
 Hospitalist 55 (25.6)
 Intensivist 194 (90.2)
 Fellow 129 (60.0)
 Resident 165 (76.7)
(Continued )
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(1,639; 2.9%), hands-on care (1,828; 3.3%), and ad-
ministrative/supportive tasks (4,768; 8.5%). The most 
frequent interventions were discontinuation of clini-
cally unwarranted therapy (8,842; 15.8%), renal dos-
age adjustments in patients not receiving continuous 
renal replacement therapy (CRRT) (8,557; 15.3%), in-
itiation of nonantimicrobial therapy (7,764; 13.9%), 
and antimicrobial therapy initiation and streamlining 
(5,019; 9.0%). The least commonly accepted inter-
ventions were medication route for resolving shock 
management (percentage accepted: 60.5%) and pre-
vention of unnecessary high-cost medication (93.7%). 
Interventions from the five most validated interven-
tion categories used in our sensitivity analysis totaled 
9,175 (16.4% of all accepted interventions) (Table 2).
The CA generated from ICU pharmacist recom-
mendations totaled $23,404,089 in six sections: ADE 
prevention (CA: $5,822,539; percentage of total CA: 
24.9%), resource utilization ($4,491,318; 19.2%), indi-
vidualization of patient care ($9,680,036; 41.4%), pro-
phylaxis ($1,414,465; 6.0%), hands-on care ($1,339,621; 
5.7%), and administrative/supportive ($656,110; 
2.8%). The areas of greatest CA were medication 
route for hypertensive crisis management ($3,436,598; 
14.7%), major ADE prevention ($3,242,171; 13.9%), 
and antimicrobial therapy initiation and streamlining 
($3,088,944; 13.2%). In our sensitivity analysis of inter-
ventions with the highest level of evidence, CA from 
the five most validated intervention categories totaled 
$7,961,681 (34.0% of CA from all accepted interven-
tions) (Table 2).
When considering all accepted interventions, av-
erage CA was $418 per intervention, $845 per patient 
each day, and $7,435 per ICU pharmacist shift. The an-
nualized CA from an ICU pharmacist was $1,784,302. 
The potential monetary CA to pharmacist salary ratio 
was $9.6:1. When considering accepted interventions 
from the five most validated intervention categories, 
average CA was $868 per intervention, $288 per pa-
tient each day, and $2,529 per ICU pharmacist shift. 
Considering these categories only, the annualized CA 
from an ICU pharmacist was $606,990, and the poten-
tial monetary CA to pharmacist salary ratio was $3.3:1.
DISCUSSION
This is the first multicenter prospective study to compre-
hensively classify interventions performed by pharma-
cists in adult ICUs and quantify potential CA generated 
through these interventions. The CA generated from 215 
pharmacists practicing in the ICU over the study period 
totaled over 23 million U.S. dollars. This CA resulted 
from pharmacists intervening almost 56,000 times over 
Institution type, n (%)  
 Academic medical center 38 (44.7)
 Community teaching 30 (35.3)
 Community nonteaching 16 (18.8)
 Government 1 (1.2)
Shift duration (hr), n (%)  
 8 2,452 (77.9)
 10 552 (17.5)
 12 51 (1.6)
 Other 93 (3.0)
Shifts worked, median (IQR) 17 (6–20)
Direct patient care duration per shift  
 (hr), median (IQR)
5.5 (4–8)
Prospective order verification duration  
 per shift (hr), median (IQR)
4 (0–6)
Services rounded with each day, n (%)  
 0 231 (7.4)
 1 1,945 (62.8)
 2 653 (21.1)
 3 165 (5.3)
 4 or more 105 (3.4)
Patients cared for per shift (n),  
 median (IQR)
15 (12–22)
Years in practice (yr), n (%)  
 ≤ 1 27 (12.6)
 > 1 to 3 74 (34.4)
 > 3 to 6 50 (23.3)
 > 6 to 12 40 (18.6)
 ≥ 12 24 (11.2)
Board certified, n (%) 174 (81.0)
IQR = interquartile range.
aCumulative percentage exceeds 100% because many 
pharmacists practice in multiple areas.
bCumulative percentage exceeds 100% because multiple 
providers in practice areas and many pharmacists practice in 
multiple practice areas.
TABLE 1. (Continued ).
ICU Pharmacist Characteristics
Characteristics
ICU Pharmacist  
(N = 215)
Observational Study
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TABLE 2. 






Section 1: Adverse drug event prevention 5,777 (97.9) 5,822,539
 Major ADE prevention 968 (97.2) 3,242,171
 Minor ADE prevention 1,894 (98.7) 772,766
 Medication reconciliation resulting in major ADE prevention 170 (99.4) 569,390
 Medication reconciliation resulting in minor ADE prevention 696 (96.8) 328,687
 Recommend laboratory monitoring 2,049 (98.3) 909,525
Section 2: Resource utilization 12,630 (97.9) 4,491,318
 Preventing unnecessary laboratories and/or tests 415 (98.3) 8,085
 Prevention of inappropriate screening of heparin induced thrombocytopenia 40 (97.6) 31,843
 Medication route: IV to oral conversion 2,908 (97.6) 159,419
 Medication route: hypertensive crisis management 164 (97.6) 3,436,598
 Medication route: resolving shock management 23 (60.5) 1,716
 Discontinuation of clinically unwarranted therapy 8,842 (98.3) 604,881
 Prevention of unnecessary high-cost medication 238 (93.7) 248,776
Section 3: Individualization of patient care 29,284 (98.3) 9,680,036
 Dosage adjustment: continuous renal replacement therapy 712 (98.5) 1,813,357
 Dosage adjustment: no continuous renal replacement therapy 8,557 (98.6) 1,398,814
 Antimicrobial therapy initiation and streamlining 5,019 (97.0) 3,088,944
 Anticoagulant therapy management 1,806 (98.7) 1,262,069
 Initiation of nonantimicrobial therapy 7,764 (98.2) 1,307,535
 Antimicrobial pharmacokinetic evaluation 4,398 (99.1) 740,667
 Total parenteral nutrition management 1,028 (99.1) 68,650
Section 4: Prophylaxis 1,639 (99.5) 1,414,465
 Change venous thromboembolism prophylaxis to most appropriate agent 329 (100) 27,610
 Initiation of venous thromboembolism prophylaxis 755 (99.2) 1,249,110
 Initiation of stress ulcer prophylaxis 375 (99.5) 21,251
 Initiation of ventilator associated pneumonia prophylaxis with chlorhexidine 180 (99.5) 116,494
Section 5: Hands-on care 1,828 (98.6) 1,339,621
 Bedside monitoring 1,150 (98.5) 446,798
 Emergency code blue participation 213 (99.1) 327,498
 Rapid response team participation 82 (97.6) 13,810
 Emergency code stroke participation 43 (100) 29,311
 Emergency code sepsis participation 23 (100) 36,453
 Blood factor stewardship 36 (100) 346,609
 Emergency procedural sedation or rapid sequence  
 intubation participation
131 (99.2) 36,333
 Medication teaching or discharge education 146 (97.3) 100,067
 Culture follow-up after emergency department discharge 4 (100) 2,742
 Antivenin stewardship 0 0
(Continued )
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the course of greater than 27,000 patient days. In total, 
99.4% of these interventions were accepted. ICU phar-
macists generated $7,435 in CA per shift when all inter-
ventions were considered and $2,529 in CA per shift 
when only the most validated intervention categories 
were used. A significant portion of CA resulted from 
interventions that individualized patient care, prevented 
ADEs, and used resources more effectively. The potential 
monetary CA to pharmacist salary ratio for ICU phar-
macists appears to be between $3.3:1 and $9.6:1.
Major ADE prevention provided the second largest 
amount of CA among the six intervention categories. 
The use of multiple agents with a narrow therapeutic 
index in critically ill patients with altered pharmacoki-
netics and pharmacodynamics places these patients at 
great risk for complications (20). The significant impact 
pharmacists have on ADE prevention aligns with results 
from a landmark trial, which described a 66% relative 
risk reduction in ADEs following inclusion of a clinical 
pharmacist (5). In addition to preventing almost 3,000 
ADEs during direct and decentralized patient care ac-
tivities, 866 additional ADEs were prevented as a result 
of interventions made following medication reconcilia-
tion. For critically ill patients, determining appropriate 
medication dosages, time of last dose, presence of med-
ications that may result in withdrawal symptoms, and 
duplicative therapies are the most common interven-
tions that prevent an ADE (21, 22).
Approximately one fifth of ICU pharmacist inter-
ventions supported more efficient utilization of 
healthcare resources. Pharmacists in the ICU com-
monly converted more expensive IV medications 
to oral dosage forms with similar efficacy or discon-
tinue certain prophylactic medications when they are 
no longer indicated. These are common practices that 
often are performed pursuant to a protocol or col-
laborative practice agreement and can reduce ADEs 
and decrease prescription costs at hospital discharge 
(23, 24). Improved management of hypertensive cri-
ses was the intervention associated with the greatest 
CA in this study. Additionally, antimicrobial agents 
were frequently discontinued because their empirical 
use was no longer necessary or a shorter duration of 
use that still would adequately treat a presumed or 
confirmed infection was deemed appropriate (25). 
Finally, interventions that improved resource utiliza-
tion also frequently reduced the use of medications 
that are on shortage in the United States. These stew-
ardship activities are imperative and challenging in 
an era of medication shortages but are necessary to 
maintain a medication’s stock for treating the most 
critical and compelling indications and patients (26). 
ICU pharmacists are well positioned to incorporate 
the costs and availability of medications into the clin-
ical decision-making process and patient care (27).
Individualizing therapies for specific patients was 
the most common classification of intervention per-
formed by ICU pharmacists, representing 52.4% 
of all included interventions. These interventions 
represented approximately 41% of the CA gener-
ated from ICU pharmacist recommendations. The 
pharmacists’ ability to individualize antimicrobial 
dosing initially and in response to pharmacoki-
netic and pharmacodynamic monitoring variables in 
Section 6: Administrative and supportive tasks 4,768 (98.7) 656,110
 Drug information consultation 2,174 (99.0) 245,836
 Drug information consultation: toxicology specific 75 (100) 31,833
 Patient own medication evaluation 335 (98.5) 130,154
 Therapeutic interchange 290 (98.6) 15,350
 Pharmacist provided drug protocol management pursuant to collaborative 
practice agreement
1,803 (98.4) 197,122
 Rejection of a restricted medication 91 (100) 35,815
Total 55,926 (99.4) 23,404,089
Values presented as number of accepted interventions (percentage of interventions accepted in section or subsection).
TABLE 2. (Continued ).
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patients with renal dysfunction, especially those re-
ceiving CRRT, significantly impact patient care (28). 
Additionally, ICU pharmacists were active in deter-
mining the most appropriate empirical antimicrobial 
therapies and de-escalating to definitive therapy or 
discontinuing treatment in these complex patients. 
Pharmacists are best positioned to ensure patient care 
is individualized with regard to the “five rights” of 
medication use: the right patient, the right drug, the 
right time, the right dose, and the right route (29).
A pharmacist intervention to ensure prophylaxis 
was provided for patients at risk for preventable com-
plications of critical illness was performed infrequently, 
totaling less than 3% of interventions and approximately 
6% of CA. Although these interventions are not often 
viewed as highly impactful, they do result in a reduced 
rate of complications in high-risk patients and are pro-
cesses that can be protocolized at many institutions 
(23, 24). ICU pharmacists also were involved in the in-
frequent but highly complex activities that represent 
hands-on care, which accounted for approximately 3% 
of interventions and almost 6% of CA. They commonly 
participated in emergency code blue (i.e., cardiac arrest) 
response, which has been shown to improve compliance 
with advanced cardiac life support guidelines (30, 31). 
Additionally, ICU pharmacists were active in acute 
stroke management, which frequently reduces door-to-
needle times and increases the proportion of patients 
who are eligible to receive thrombolytics (32, 33). Finally, 
blood factor stewardship represented a significant por-
tion of CA for this category of intervention. In these 
activities, pharmacists ensure appropriate use of blood 
factor products and dosages is achieved (34, 35). In crit-
ical and emergent situations, pharmacists bring expertise 
that complement other team members and elevate the 
clinical and safety outcomes for patients (36).
Fundamentally, our analysis provides estimates of 
CA, but such estimates are sensitive to underlying 
assumptions. We used an evidence-based framework for 
the types of interventions and associated CA from pub-
lished literature to classify interventions and quantify 
their CA; however, these CA values are imperfect and 
may result in both over- or underestimation of the true 
CA, depending on the patient, pharmacist institution, 
and situation (17). We used fixed costs per intervention 
documented, although we acknowledge that the costs 
may vary by center, participant, and other conditions 
including medication costs. Specifically for categories 
such as ADE avoidance, our approach assumed that 
pharmacist interventions consistently lead to avoidance 
of an adverse event that was destined to occur (i.e. 100% 
probability of harm), which we recognize may not al-
ways be a valid assumption and risk overinflating CA 
estimates given that an adverse event would not have 
occurred or the intervention may have ultimately been 
detected by another member of the healthcare team. A 
recent scoping review of CA from pharmacist interven-
tions demonstrated high risk of inflation and limited 
assessment of probability of harm (38). We attempted 
to mitigate this risk with the incorporation of a sen-
sitivity analysis using only the CA categories with the 
highest levels of evidence, although only five interven-
tion categories have CA values that come from con-
trolled studies. The results from the sensitivity analysis 
that used only these intervention categories was used 
to anchor the lowest suspected CA from ICU pharma-
cists. Although the rate and type of preventable ADEs 
were determined in a similar manner to past studies, the 
counterfactual or true extent of ADE development can-
not be known. Participating pharmacists were encour-
aged to err on the side of underemphasizing the extent 
of an ADE, which may have resulted in an underappre-
ciation of the true CA from ADE prevention. In studies 
of this nature, the reduction in potential harm and asso-
ciated CA from an intervention is difficult to precisely 
determine. In addition to a probabilistic factor that an 
identified scenario actually leads to harm, the CA of an 
intervention likely varies per patient, and again we used 
fixed estimates for these categorizations. Nevertheless, 
a substantial decrease in the quantity of accepted inter-
ventions or actual CA from these interventions would 
need to occur to cause the return on investment for ICU 
pharmacists demonstrated in this study to approach un-
acceptable values. Even for the cost estimates that were 
directly quantifiable such as direct pharmaceutical costs 
of agents, we recognize that costs may vary significantly 
per center. Furthermore, the evidence-based framework 
only included categorized interventions for which there 
were pre-existing data (17). Although this framework is 
based on published literature, it has not been prospec-
tively validated with probabilistic CA considerations 
included. This also implies that if an intervention was 
not included as a category, we were unable to capture 
activities not quantified in the framework that may still 
generate CA for critically ill patients. Although catego-
rizing CA in healthcare is a difficult task, particularly 
Rech et al
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in critically ill patients, proposed guidance has recently 
been published for CA studies in pharmacy practice, in-
cluding a probabilistic framework (39).
There are several ways in which CA may be over-
estimated. In addition to the aforementioned chal-
lenges of fixed CA values, participants may have 
documented accepted interventions more frequently 
than accepted or inflated interventions performed, al-
though attempts to reduce this Hawthorne effect were 
instituted (37). Although selection bias was mitigated 
by the diversity of pharmacists with regard to train-
ing, experience, and hospital, we cannot rule out the 
possibility that pharmacists electing to participate in 
the study are more likely to either make interventions 
and/or document those interventions compared with 
pharmacists not participating. Conversely, CA may 
have been underestimated as well through a host of 
factors. Additionally, the quantity and type of inter-
ventions were likely incomplete because data collec-
tion was performed in real time. A greater quantity 
of interventions may have been performed than were 
documented. Furthermore, sustained interaction be-
tween an ICU pharmacist and healthcare team may 
alter the potential CA of a pharmacist over time. When 
first incorporating an ICU pharmacist, potential CA 
may be much larger as pharmacists likely have a larger 
impact given protocol develop, education, implemen-
tation of best practice, and other initial benefits. This 
time-varying CA of ICU pharmacists is hypothesis 
generating only as we were not able to evaluate in our 
study. Although many ICU clinical pharmacists were 
included, these results may not be generalizable to all 
ICU pharmacists and hospitals. Additionally, there 
was substantial variability in the number of shifts 
contributed by ICU pharmacists (IQR, 6—20); it is 
unclear how this affected our findings. Finally, many 
other factors may have impacted the quantity and 
types of interventions as well as their acceptance, in-
cluding interpersonal traits, professional relationships 
with other healthcare providers, and patient volume 
and complexity during the study period.
CONCLUSIONS
ICU pharmacists resulted in significant avoidance of 
healthcare costs, particularly in the areas of individu-
alization of patient care, ADE prevention, and resource 
utilization. The potential monetary CA to pharmacist 
salary ratio for ICU pharmacists appears to be between 
$3.3:1 and $9.6:1.
ACKNOWLEDGMENT
We would like to thank William Adams, PhD, for his 
help in consultation on study design and methods.
 1 Department of Pharmacy, Loyola University Medical Center, 
Maywood, IL.
 2 Department of Emergency Medicine, Loyola University 
Medical Center, Maywood, IL.
 3 Department of Internal Medicine, Rush Medical College, 
Chicago, IL.
 4 Department of Pharmacy, Froedtert Hospital, Milwaukee, 
WI.
 5 Department of Surgery, Medical College of Wisconsin, 
Milwaukee, WI.
 6 Department of Pharmacy, Ohio State University Medical 
Center, Columbus, OH.
 7 Department of Pharmacy, Erlanger Medical Center, 
Chattanooga, TN.
 8 Department of Pharmacy, University of Kentucky HealthCare, 
Lexington, KY.
 9 Department of Pharmacy Practice and Science, University of 
Kentucky College of Pharmacy, Lexington, KY.
Supplemental digital content is available for this article. Direct 
URL citations appear in the printed text and are provided in the 
HTML and PDF versions of this article on the journal’s website 
(http://journals.lww.com/ccejournal).
The authors have disclosed that they do not have any potential 
conflicts of interest.
PHARM-CRIT Investigators are listed in Supplemental Table 2 
(http://links.lww.com/CCX/A870).
For information regarding this aricle, E-mail: mrech@lumc.edu
REFERENCES
 1. Emergency Department Visits. Available at: https://www.cdc.
gov/nchs/fastats/emergency-department.htm. Accessed July 
25, 2019
 2. Halpern NA, Pastores SM: Critical care medicine in the United 
States 2000-2005: An analysis of bed numbers, occupancy 
rates, payer mix, and costs. Crit Care Med 2010; 38:65–71
 3. NIH consensus development conference on critical care med-
icine. Crit Care Med 1983; 11:466–469
 4. Montazeri M, Cook DJ: Impact of a clinical pharmacist in a 
multidisciplinary intensive care unit. Crit Care Med 1994; 
22:1044–1048
 5. Leape LL, Cullen DJ, Clapp MD, et al: Pharmacist participation 
on physician rounds and adverse drug events in the intensive 
care unit. JAMA 1999; 282:267–270
 6. Zampieri FG, Salluh JIF, Azevedo LCP, et al; ORCHESTRA 
Study Investigators: ICU staffing feature phenotypes and their 
Observational Study
Critical Care Explorations www.ccejournal.org     9
relationship with patients’ outcomes: An unsupervised machine 
learning analysis. Intensive Care Med 2019; 45:1599–1607
 7. MacLaren R, Bond CA, Martin SJ, et al: Clinical and eco-
nomic outcomes of involving pharmacists in the direct care 
of critically ill patients with infections. Crit Care Med 2008; 
36:3184–3189
 8. MacLaren R, Bond CA: Effects of pharmacist participation 
in intensive care units on clinical and economic outcomes of 
critically ill patients with thromboembolic or infarction-related 
events. Pharmacotherapy 2009; 29:761–768
 9. Hammond DA, Flowers HJC, Meena N, et al: Cost avoidance 
associated with clinical pharmacist presence in a medical in-
tensive care unit. J Am Coll Clin Pharm 2019; 2:610–615
 10. Rudis MI, Brandl KM: Position paper on critical care pharmacy 
services. Society of Critical Care Medicine and American 
College of Clinical Pharmacy Task Force on Critical Care 
Pharmacy Services. Crit Care Med 2000; 28:3746–3750
 11. Lat I, Paciullo C, Daley MJ, et al: Position paper on critical 
care pharmacy services: 2020 update. Crit Care Med 2020; 
48:e813–e834
 12. Dager W, Bolesta S, Brophy G, et al. An opinion paper outlining 
recommendations for training, credentialing, and documenting 
and justifying critical care pharmacy services. Pharmacotherapy 
2011; 31:135e–175e
 13. ASHP’s Section Advisory Groups (SAG) Emergency Medicine. 
Available at: https://www.ashp.org/pharmacy-practice/
resource-centers/emergency-medicine. Accessed July 25, 
2019
 14. Harris PA, Taylor R, Thielke R, et al: Research electronic data 
capture (REDCap)–A metadata-driven methodology and 
workflow process for providing translational research infor-
matics support. J Biomed Inform 2009; 42:377–381
 15. Harris PA, Taylor R, Minor BL, et al; REDCap Consortium: 
The REDCap consortium: Building an international commu-
nity of software platform partners. J Biomed Inform 2019; 
95:103208
 16. Obeid JS, McGraw CA, Minor BL, et al: Procurement of 
shared data instruments for research electronic data capture 
(REDCap). J Biomed Inform 2013; 46:259–265
 17. Hammond DA, Gurnani PK, Flannery AH, et al: Scoping review 
of interventions associated with cost avoidance able to be per-
formed in the intensive care unit and emergency department. 
Pharmacotherapy 2019; 39:215–231
 18. Bureau of Labor Statistics: CPI-All Urban Consumers (Current 
Series). Available at: https://data.bls.gov/pdq/. Accessed 
February 2, 2019
 19. Bureau of Labor Statistics: Occupational Outlook Handbook 
(Pharmacists). Available at: https://www.bls.gov/ooh/health-
care/pharmacists.htm#tab-1. Accessed December 4, 2019
 20. Blix HS, Viktil KK, Moger TA, et al: Drugs with narrow thera-
peutic index as indicators in the risk management of hospital-
ised patients. Pharm Pract (Granada) 2010; 8:50–55
 21. Institute for Healthcare Improvement: How-to Guide: 
Prevent Adverse Drug Events by Implementing Medication 
Reconciliation. Cambridge, MA, Institute for Healthcare 
Improvement, 2011. Available at: http://www.ihi.org/resources/
Pages/Tools/HowtoGuidePreventAdverseDrugEvents.aspx. 
Accessed February 4, 2019
 22. Tully AP, Hammond DA, Li C, et al: Evaluation of medication 
errors at the transition of care from an ICU to mon-ICU loca-
tion. Crit Care Med 2019; 47:543–549
 23. Buckley MS, Park AS, Anderson CS, et al: Impact of a clinical 
pharmacist stress ulcer prophylaxis management program on 
inappropriate use in hospitalized patients. Am J Med 2015; 
128:905–913
 24. Hammond DA, Killingsworth CA, Painter JT, et al: Impact of tar-
geted educational interventions on appropriateness of stress 
ulcer prophylaxis in critically ill adults. Pharm Pract (Granada) 
2017; 15:948
 25. Shah NH, Do LV, Petrovich J, et al: Reducing cost and intra-
venous duration of nicardipine in intracerebral hemorrhage 
patients via an interdisciplinary approach. J Stroke Cerebrovasc 
Dis 2016; 25:2290–2294
 26. Spellberg B, Rice LB: Duration of antibiotic therapy: Shorter is 
better. Ann Intern Med 2019; 171(3):210–211
 27. Mazer-Amirshahi M, Goyal M, Umar SA, et al: U.S. drug short-
ages for medications used in adult critical care (2001-2016). 
J Crit Care 2017; 41:283–288
 28. Hammond DA, Chiu T, Painter JT, et al: Nonpharmacist 
health care providers’ knowledge of and opinions regarding 
medication costs in critically ill patients. Hosp Pharm 2018; 
53:188–193
 29. Rhodes A, Evans LE, Alhazzani W, et al: Surviving sepsis cam-
paign: International guidelines for management of sepsis and 
septic shock: 2016. Crit Care Med 2017; 45:486–552
 30. Grissinger M. The five rights. P T 2010; 35:542.
 31. Draper HM, Eppert JA: Association of pharmacist presence 
on compliance with advanced cardiac life support guidelines 
during in-hospital cardiac arrest. Ann Pharmacother 2008; 
42:469–474
 32. McAllister MW, Chestnutt JG: Improved outcomes and cost 
savings associated with pharmacist presence in the emer-
gency department. Hosp Pharm 2017; 52:433–437
 33. Rech MA, Bennett S, Donahey E: Pharmacist participation in 
acute ischemic stroke decreases door-to-needle time to re-
combinant tissue plasminogen activator. Ann Pharmacother 
2017; 51:1084–1089
 34. Montgomery K, Hall AB: Impact of an emergency medicine 
pharmacist on time to thrombolysis in acute ischemic stroke: 
Strength of association. Am J Emerg Med 2017; 35:345
 35. Trueg AO, Lowe C, Kiel PJ: Clinical outcomes of a pharmacy-
led blood factor stewardship program. Am J Ther 2017; 
24:e643–e647
 36. Rech MA, Adams W, Smetana KS, et al: PHarmacist Avoidance 
or Reductions in Medical Costs in Patients Presenting the 
EMergency Department: PHARM-EM study. Crit Care Explor 
2021; 3:e0406
 37. Sedgwick P, Greenwood N: Understanding the Hawthorne 
effect. BMJ 2015; 351:h4672
 38. Narayan SW, Abraham I, Erstad BL, et al: Methods used to 
attribute costs avoided from pharmacist interventions in 
acute care: A scoping review. Am J Health Syst Pharm 2021; 
78:1576–1590
 39. Patanwala AE, Narayan SW, Haas CE, et al: Proposed guid-
ance on cost-avoidance studies in pharmacy practice. Am J 
Health Syst Pharm 2021; 78:1559–1567
